两基因表达比值作为他莫昔芬治疗乳腺癌的预测指标：来自荟萃分析的证据。

Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis.

作者信息

Zhao Lin, Zhu Shimiao, Gao Ying, Wang Yaogang

机构信息

International Medical School, Tianjin Medical University, 300070, Tianjin, China.

出版信息

Tumour Biol. 2014 Apr;35(4):3113-7. doi: 10.1007/s13277-013-1403-x. Epub 2013 Nov 22.

DOI:10.1007/s13277-013-1403-x

PMID:24264313

Abstract

A HOXB13-to-IL17BR expression ratio was previously identified to predict a clinical outcome of breast cancer patients treated with adjuvant tamoxifen. A large number of studies were addressed to confirm its function as a predictor of breast cancer outcome treated with tamoxifen. However, conflicting results were got. In this study, a systematic search of databases was carried out, and other relevant papers were also identified. Then, the analyses were conducted according to the PRISMA and MOOSE guidelines. After full review, 11 studies with a total of 2,958 participants were deemed eligible and were included in the study. Pooled results revealed that women with higher HOXB13-to-IL17BR expression ratio had significantly worse outcomes in breast patients treated with tamoxifen, especially for those who are negative of node.

摘要

先前已确定HOXB13与IL17BR的表达比值可预测接受辅助他莫昔芬治疗的乳腺癌患者的临床结局。大量研究致力于证实其作为他莫昔芬治疗乳腺癌结局预测指标的功能。然而，得到的结果相互矛盾。在本研究中，我们对数据库进行了系统检索，并确定了其他相关论文。然后，根据PRISMA和MOOSE指南进行分析。经过全面审查，11项研究共2958名参与者被认为符合条件并纳入研究。汇总结果显示，HOXB13与IL17BR表达比值较高的女性在接受他莫昔芬治疗的乳腺癌患者中结局明显更差，尤其是那些淋巴结阴性的患者。